Jason R Gotlib
Overview
Explore the profile of Jason R Gotlib including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
966
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mosna F, Borlenghi E, Litzow M, Byrd J, Papayannidis C, Tecchio C, et al.
Haematologica
. 2024 Oct;
110(3):608-620.
PMID: 39385741
Acute myeloid leukemia (AML) is mainly a disease of the elderly: however, knowledge about the outcomes of treatment of core-binding factor (CBF) AML in an older population is limited. We...
2.
Zhang H, Chien M, Hou Y, Shomali W, Brar R, Ho C, et al.
Blood Adv
. 2022 Apr;
7(1):190-194.
PMID: 35381066
Cyclic thrombocytopenia (CTP) is a rare disease of periodic platelet count oscillations. The pathogenesis of CTP remains elusive. To study the underlying pathophysiology and genetic and cellular associations with CTP,...
3.
Shomali W, Brar R, Arekapudi S, Gotlib J
Hemoglobin
. 2019 Oct;
43(4-5):273-276.
PMID: 31657650
High oxygen affinity hemoglobins (Hbs), characterized by a decreased ability to release oxygen to the tissues and a left-shifted oxygen dissociation curve, are a rare cause of secondary erythrocytosis. Here,...
4.
Zhang H, Wilmot B, Bottomly D, Dao K, Stevens E, Eide C, et al.
Blood
. 2019 Aug;
134(11):867-879.
PMID: 31366621
Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) are a group of rare and heterogeneous myeloid disorders. There is strong morphologic resemblance among these...
5.
Das B, Pal B, Bhuyan R, Li H, Sarma A, Gayan S, et al.
Cancer Res
. 2019 Jul;
79(16):4015-4025.
PMID: 31266772
Cancer stem cells (CSC) maintain both undifferentiated self-renewing CSCs and differentiated, non-self-renewing non-CSCs through cellular division. However, molecular mechanisms that maintain self-renewal in CSCs versus non-CSCs are not yet clear....
6.
Li P, Shahmarvand N, Lynch D, Gotlib J, Merker J, Zehnder J, et al.
Int J Lab Hematol
. 2019 Feb;
41(3):345-352.
PMID: 30811101
Introduction: Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a rare disease in the 2016 revised World Health Organization (WHO) classification. Diagnostic criteria include the following: persistent thrombocytosis (>450 ...
7.
Munoz-Gonzalez J, Jara-Acevedo M, Alvarez-Twose I, Merker J, Teodosio C, Hou Y, et al.
Blood Adv
. 2018 Oct;
2(21):2814-2828.
PMID: 30373888
Systemic mastocytosis (SM) is a highly heterogeneous disease with indolent and aggressive forms, with the mechanisms leading to malignant transformation still remaining to be elucidated. Here, we investigated the presence...
8.
Menghrajani K, Boonstra P, Mercer J, Perkins C, Gowin K, Weber A, et al.
Leuk Lymphoma
. 2018 Sep;
60(4):1036-1042.
PMID: 30234400
JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008...
9.
Ma V, Boonstra P, Menghrajani K, Perkins C, Gowin K, Mesa R, et al.
Clin Lymphoma Myeloma Leuk
. 2018 Mar;
18(5):e201-e210.
PMID: 29574002
Introduction: In the era before Janus kinase (JAK) inhibitors, cytogenetic information was used to predict survival in myelofibrosis patients. However, the prognostic value of cytogenetics in the setting of JAK...
10.
Chisholm K, Merker J, Gotlib J, Gitana G, Lefterova M, Zehnder J, et al.
Am J Clin Pathol
. 2015 Mar;
143(4):527-34.
PMID: 25780004
Objectives: We sought to determine the significance of bright CD45 expression on mast cells in cases of systemic mastocytosis vs mast cells in bone marrows uninvolved by systemic mastocytosis and...